Application of targeted drugs combined with chemotherapy in improving clinical symptoms and preventing adverse reactions in patients with advanced non-small cell lung cancer
Objective To analyze the effects of targeted drugs combined with chemotherapy on improving clinical symptoms and preventing adverse reactions in patients with advanced non-small cell lung cancer (NSCLC). Methods NSCLC patients admitted to our hospital were selected as study samples (70 cases), and were divided into two groups according to random number table method, namely control group and observation group, which were given chemotherapy (etoposide + cisplatin) and chemotherapy combined with targeted drugs (gefitinib), respectively. The clinical therapeutic effect, improvement of clinical symptoms and incidence of adverse reactions were compared between the two groups. Results The ORR of the control group was 34.29％, and that of the observation group was 57.14％, and the difference of each grade was statistically significant (P＜0.05). Before treatment, there was no statistically significant difference in clinical symptom improvement score between the two groups (P＞0.05). After treatment, clinical symptom improvement score in the observation group was lower than that in the control group, with statistically significant difference (P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion Targeted drugs combined with chemotherapy can improve the clinical symptoms of patients with NSCLC and improve the therapeutic effect.
万方数据
